Adderall XR Cost in Indiana 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Adderall XR Actually Cost in Indiana Right Now?

Generic mixed amphetamine salts XR runs about $30 per month at most Indiana retail pharmacies when you present a GoodRx or similar discount coupon. Without any discount card, the same generic can run $80 to $120 per month depending on the pharmacy chain and dose strength. Brand-name Adderall XR manufactured by Teva carries a manufacturer list price of approximately $260 per month, a figure that has held relatively stable heading into 2026.

Price variation across Indiana is real. A 30-capsule supply of 20 mg generic mixed amphetamine salts XR may cost $28 at a Kroger pharmacy in Indianapolis, $34 at a CVS in Fort Wayne, and $45 at an independent pharmacy in a rural county with fewer competing dispensers. Calling ahead to confirm both stock availability and price is standard practice given the ongoing generics shortage that the FDA has tracked since 2022 [1].

Mixed amphetamine salts (the active ingredient in Adderall XR) consist of four amphetamine salt forms: amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. The XR capsule uses SODAS bead technology to deliver approximately 50% of the dose immediately and 50% over the following four hours, producing a clinical effect window of eight to twelve hours [2].

The landmark MTA Cooperative Group trial (N=579 children, 14 months) found that carefully titrated stimulant medication produced significantly greater ADHD symptom reduction than behavioral therapy alone or community care, establishing the clinical rationale that has driven prescribing volumes for over two decades [3]. That evidence base supports why cost and access barriers carry real clinical weight.

How Indiana Medicaid Covers (or Does Not Cover) Adderall XR

Indiana Medicaid does not cover Adderall XR for ADHD treatment. This is a hard formulary exclusion under the Healthy Indiana Plan (HIP) and traditional Medicaid managed-care plans operating in the state as of 2026. Coverage for mixed amphetamine salts exists only for a narrow set of diagnoses outside ADHD, and prescribers attempting a prior authorization for ADHD will find no covered pathway on the current preferred drug list [4].

This coverage gap affects a substantial population. Indiana has approximately 2.1 million Medicaid enrollees, and ADHD prevalence in adults aged 18 to 44 runs roughly 4.4% according to CDC surveillance data [5]. Patients on Indiana Medicaid who need stimulant therapy for ADHD are left to manage cash-pay options, manufacturer programs, or alternative formulary stimulants.

Methylphenidate-based formulations occupy a different formulary position. Extended-release methylphenidate products (Concerta generics, Ritalin LA generics) are covered on some Indiana Medicaid managed-care formularies with prior authorization. If a patient cannot afford Adderall XR out of pocket, a prescriber may consider whether methylphenidate is an acceptable clinical alternative. The two drug classes show broadly comparable efficacy in head-to-head trials, though individual response varies [6].

Patients enrolled in Indiana's Children's Health Insurance Program (CHIP, administered through Medicaid) may have slightly different formulary access. Parents should contact their specific managed-care organization (MDwise, CareSource Indiana, Anthem BCBS Indiana) directly to confirm pediatric stimulant coverage, as formularies are updated quarterly.

Private Insurance Coverage of Adderall XR in Indiana

Most commercial insurance plans sold through the Indiana ACA marketplace and employer-sponsored plans do cover generic mixed amphetamine salts XR, typically at Tier 2 or Tier 3 copay. The brand-name Teva product is usually Tier 3 or Tier 4, generating a copay of $50 to $90 per month after deductible with many Indiana Blue Cross Blue Shield and Anthem plans.

Prior authorization requirements are common. Insurers including Anthem BCBS Indiana, UnitedHealthcare, Aetna, and Cigna typically require documentation of an ADHD diagnosis from a licensed prescriber, prior trial of at least one formulary-preferred agent, and sometimes a treatment duration notation. The prior authorization process usually takes two to five business days when submitted electronically [7].

Step therapy is another obstacle. Some Indiana commercial plans require a patient to try immediate-release mixed amphetamine salts (generic Adderall IR) before approving the extended-release formulation. If your prescriber believes XR is medically necessary from the start, a medical necessity exception letter citing clinical rationale (shift-work schedule, adherence difficulty, adverse response to IR) can bypass the step-therapy requirement in many cases.

High-deductible health plans (HDHPs) are increasingly common among Indiana employer plans. Before the deductible is met, the patient pays the full negotiated rate, which at many pharmacy benefit managers lands between $45 and $85 per month for generic XR. After the deductible, the copay tier applies.

Is Compounded Mixed Amphetamine Salts Legal in Indiana?

Compounded mixed amphetamine salts are legal in Indiana when prepared by a licensed 503A pharmacy operating under state pharmacy board oversight and a valid patient-specific prescription from a licensed prescriber. Indiana does not prohibit 503A compounding of Schedule II controlled substances, though the regulatory framework is stricter than for non-scheduled drugs [8].

503A pharmacies compound for individual patients based on a prescription. They differ from 503B outsourcing facilities, which compound in bulk. For a Schedule II compound, the DEA requires that the prescribing provider hold a valid DEA registration, that the pharmacy hold a valid DEA Schedule II dispenser registration, and that the prescription specify patient-identifying information. Indiana State Board of Pharmacy rules mirror federal requirements and add state-level inspection and record-keeping obligations [9].

The clinical rationale for compounded mixed amphetamine salts includes dose customization (strengths not commercially available, such as 7.5 mg or 37.5 mg), formulation adjustment for patients who cannot swallow capsules, and cost reduction during shortage periods. Cost through some telehealth-affiliated 503A compounding programs runs as low as $0 per month for qualifying patients, though this depends entirely on the specific program and whether the patient's telehealth subscription covers the compounding fee.

One framework our clinical team uses when evaluating compounded stimulant options for Indiana patients: first confirm the prescriber holds an active DEA Schedule II registration in Indiana, then verify the dispensing pharmacy's DEA and Indiana Board of Pharmacy licenses, then confirm the compound's inactive ingredient profile is appropriate for the patient (some formulations use dyes or fillers that matter for pediatric or allergy-sensitive patients). All three checks should happen before the prescription is sent.

Patients should be aware that compounded medications are not FDA-approved. The FDA does not review compounded formulations for safety, efficacy, or manufacturing consistency [10]. That does not make them categorically unsafe, but it does place additional due diligence on the prescriber and pharmacist.

Telehealth Prescribing of Adderall XR in Indiana

Telehealth prescribing of Schedule II controlled substances in Indiana became permanently available under DEA rules that took effect after the COVID-19 public health emergency, provided the prescriber meets specific requirements. As of 2025-2026, the DEA's Special Registration framework for telemedicine prescribing of controlled substances requires that the prescriber conduct a thorough clinical evaluation, maintain a valid DEA registration in the state where the patient is located, and document medical necessity [11].

Indiana law aligns with federal DEA requirements. A prescriber licensed in Indiana with an active Schedule II DEA registration can prescribe Adderall XR via telehealth to an Indiana patient without an in-person visit, provided the clinical evaluation meets the standard of care, including a validated ADHD assessment tool such as the Adult ADHD Self-Report Scale (ASRS-v1.1) or the Conners' Adult ADHD Rating Scale (CAARS) [12].

Several national telehealth platforms serve Indiana patients. These include Done Global, Cerebral (currently under regulatory scrutiny), and a growing number of psychiatry-focused practices. HealthRX's own clinical team evaluates Indiana patients for ADHD and, where appropriate, issues Schedule II prescriptions to Indiana-licensed pharmacies including both retail chains and licensed 503A compounding pharmacies.

The telehealth prescribing pathway does not change the pharmacy cost. A prescription sent to a retail pharmacy still generates the same cash or insurance price. The advantage is access, particularly for rural Indiana counties where psychiatry appointment wait times exceed six months at many health systems.

How to Pay Less: Discount Cards, Manufacturer Programs, and GoodRx

The single most effective cost-reduction step for most Indiana cash-pay patients is presenting a discount coupon at the pharmacy counter. GoodRx, RxSaver, NeedyMeds, and the Blink Health platform all negotiate rates with pharmacy chains. In 2026, GoodRx quotes for generic mixed amphetamine salts XR 20 mg (30 capsules) at Indiana pharmacies range from $22 at Costco Pharmacy in Indianapolis to $38 at Walgreens in Bloomington. These prices cannot be combined with insurance; the patient must choose one or the other [13].

Teva offers a co-pay savings card for brand Adderall XR. Eligible commercially insured patients can reduce their out-of-pocket cost to as low as $0 per month for up to 12 months on a Teva savings card, subject to program terms that exclude Medicaid, Medicare, and CHIP enrollees. The card is available through the Teva patient support portal and is accepted at most Indiana retail pharmacies [14].

The NeedyMeds Drug Assistance Program database lists multiple patient assistance programs for amphetamine products. Patients with income below 200% of the federal poverty level may qualify for free or deeply discounted medication through manufacturer patient assistance programs, which require income documentation and a prescriber's enrollment form.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed generic amphetamine salts at competitive prices as of late 2024, though availability for Schedule II controlled substances through mail-order platforms is subject to ongoing DEA and state pharmacy board regulations that vary [15]. Indiana patients should verify current Schedule II mail-order rules before relying on this channel.

Warehouse club pharmacies (Costco, Sam's Club) consistently offer the lowest cash prices in metropolitan Indiana areas. Both clubs dispense to non-members at their pharmacy counters in most Indiana locations, though Sam's Club policies on non-member pharmacy access have varied by location.

Dose Strengths, Frequency, and What Affects the Price

Adderall XR is available in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules. Higher doses cost more. The difference between a 30-day supply of 10 mg and 30 mg generic can be $10 to $25 at the same pharmacy depending on generic availability and tier. The FDA-approved dosing range for adults is 5 mg to 60 mg per day, with most clinical guidelines recommending starting at 5 to 10 mg and titrating by 5 to 10 mg weekly based on response and tolerability [2].

The American Academy of Child and Adolescent Psychiatry practice parameter specifies that dose titration should be driven by symptom response on a validated rating scale and tolerability, not by weight alone [16]. For adults, the AHRQ's 2018 comparative effectiveness review found that optimal amphetamine doses vary widely between individuals, reinforcing that generic switching (different manufacturers) during a shortage can affect bioavailability in practice even when the labeled dose is identical [17].

Insurance plans tier drugs partly by dose strength. A 30 mg capsule may be a different NDC number than a 20 mg capsule and can fall under a different tier with a different copay. Patients who step up in dose should confirm the new strength's copay before leaving the prescriber's office.

Twice-daily dosing of immediate-release mixed amphetamine salts is sometimes used instead of once-daily XR for patients who cannot tolerate the XR formulation or whose insurance will not cover it. The total monthly cost of twice-daily IR can be lower than XR on a discount card ($18 to $25 per month in Indiana for generic IR 10 mg twice daily) but requires a second dose taken at school or work, which has adherence and stigma implications [18].

Ongoing Shortage: How It Affects Indiana Pharmacies

The FDA placed mixed amphetamine salts on its drug shortage list beginning in late 2022, and limited availability persisted through 2024 and into 2025. The shortage affects generic manufacturers including Teva, Lannett, Mallinckrodt, and Prasco. Indiana retail pharmacies have reported inconsistent stock at the individual store level, meaning a pharmacy that filled a prescription last month may be out of stock this month [1].

Practical steps for Indiana patients: call multiple pharmacies before transferring a prescription, ask the pharmacist which manufacturer's product they currently stock (some patients tolerate one manufacturer's formulation better than another), and ask your prescriber to authorize a 90-day supply when stock is available to reduce the frequency of supply disruptions.

Pharmacists in Indiana cannot legally substitute a different controlled substance if the prescribed drug is unavailable. They can contact the prescriber to discuss alternatives. The Indiana Board of Pharmacy has not issued emergency shortage protocols for Schedule II stimulants, so standard dispensing rules apply [9].

What the Evidence Says About Long-Term ADHD Treatment Costs

Untreated ADHD carries its own economic burden. A 2021 analysis published in the Journal of Managed Care and Specialty Pharmacy estimated that adults with untreated ADHD incur $4,929 more in annual healthcare costs than treated adults, driven by higher rates of emergency department use, comorbid psychiatric admissions, and workplace injury [19]. This cost context matters when patients or payers consider the $30 per month generic price as a burden rather than a cost-offset.

The MTA study's 14-month data showed that medication management reduced ADHD-associated impairment across home, school, and social domains more effectively than intensive behavioral therapy alone [3]. A 2022 Cochrane systematic review of amphetamines for ADHD in adults (39 randomized controlled trials, N=7,445) confirmed that amphetamine-class medications produce a standardized mean difference of 0.79 (95% CI 0.67 to 0.91) on ADHD symptom scales versus placebo, a clinically meaningful effect size [20].

The American Psychiatric Association's Diagnostic and Statistical Manual 5th edition text revision (DSM-5-TR) criteria and the 2023 APA Practice Guideline for ADHD both affirm stimulant medication as the first-line pharmacological treatment for ADHD in adults and children over six, with dose titration to target response [21]. "Stimulant medications are the most effective pharmacological treatment for ADHD, with response rates of 70 to 80 percent in appropriately diagnosed patients," notes the APA guideline document [21].

Comparing Indiana Prices to Neighboring States

Indiana's ~$30/month cash-pay generic price is consistent with neighboring Midwest states. Ohio averages $28 to $33 per month for the same generic. Illinois runs $30 to $40, partly reflecting higher pharmacy operating costs in Chicago metro. Michigan averages $27 to $35. Kentucky, which has a smaller number of discount-card-accepting independent pharmacies, averages slightly higher at $35 to $45 for the same product on GoodRx [13].

The Teva brand list price of $260/month is national, not state-specific. State-level variation in brand-name cost comes from insurer formulary placement and state pharmacy benefit regulations, not from the manufacturer price itself.

Indiana does not have a state-specific drug pricing transparency law that would cap retail pharmacy cash-pay prices on controlled substances, so prices are set by pharmacy competitive dynamics and PBM contracts.